Physician profile
Alan David Roumm
NPI 1457375610
$1,984.75
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2020: $864.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $433.86 | 2019-2020 | |
| Ucb, INC. | $294.08 | 2019-2020 | |
| Abbvie INC. | $192.09 | 2019-2020 | |
| Janssen Biotech, INC. | $181.27 | 2019-2020 | |
| Glaxosmithkline, LLC. | $164.62 | 2019-2020 | |
| Genentech USA, INC. | $158.19 | 2019-2020 | |
| Pfizer INC. | $140.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $95.29 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $78.14 | 2019-2020 | |
| Lilly USA, LLC | $62.50 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $47.78 | 2019 | |
| Genzyme Corporation | $44.53 | 2020 | |
| Celgene Corporation | $40.14 | 2019 | |
| Pacira Therapeutics, INC. | $24.04 | 2019 | |
| Avion Pharmaceuticals | $14.72 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $13.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Roumm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.